Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH - Trial NCT04944654
Access comprehensive clinical trial information for NCT04944654 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chelsea and Westminster NHS Foundation Trust and is currently Not yet recruiting. The study focuses on Human Immunodeficiency Virus. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chelsea and Westminster NHS Foundation Trust
Timeline & Enrollment
Phase 4
Feb 01, 2022
Oct 01, 2023
Primary Outcome
Measure of viral load
Summary
This is a clinical trial for TPLWH (Trans People Living with HIV) who are stable on cART with
 an undetectable viral load or a detectable viral load but no resistance to NRTIs and InSTI.
 Following written consent and screening procedures, study subjects will undergo a switch (or
 will restart) of their combination antiretroviral therapy (cART) to Biktarvy. The goal of
 this research project is to recruit an understudied population into a controlled clinical
 trial aimed at optimizing TPLWH cART. This will be demonstrated by measuring viral load
 outcomes at regular intervals, with a focus on viral load results 48 weeks after Biktarvy
 initiation (primary outcome).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04944654
Non-Device Trial